Dallas Salazar
IPOs, contrarian, long/short equity, long-term horizon

Despite A Bumpy Road Ahead I'm Bullish On CareDx

I very rarely invest in biotech stocks anymore after having the summer of a lifetime in 2012. It was during that summer that I successfully traded the run-up and/or post approval pops of Arena Pharmaceuticals, Rosetta Genomics, Vivus Inc., Amarin Corp, and Orexigen Therapeutics, Inc. It was that summer of obesity, fish oils, and RNA that taught me just how fickle the biotech markets could be and just how quickly a newcomer could lose his shirt buying at the wrong time. I mean somebody was buying when I was hitting sell at the post approval highs and for the most part all these years later that somebody still hasn't recovered. Since then I've avoided anything to do with biotech outside...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details